Effects of short-term estradiol and norethindrone acetate treatment on the breasts of normal postmenopausal women

Menopause

Volumn 20, Issue 5, 2013, Pages 496-503

  Cheng, Guojun ^a,b   Butler, Ryan ^c   Warner, Margaret ^c   Gustafsson, Jan Åke ^a,c   Wilczek, Brigitte ^d   Landgren, Britt Marie ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c University of Houston   (United States)

^d ST GÖRAN S HOSPITAL   (Sweden)

Author keywords

Breast; Estrogen receptor; Hormone therapy; Menopause; Progesterone receptor

Indexed keywords

ANDROGEN RECEPTOR; CHOLESTEROL; COLLAGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTRADIOL; ESTROGEN RECEPTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; KI 67 ANTIGEN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NORETHISTERONE ACETATE; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; BREAST; BREAST BIOPSY; CELL PROLIFERATION; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; HISTOLOGY; HORMONAL THERAPY; HOT FLUSH; HUMAN; HUMAN TISSUE; KIDNEY FUNCTION; LIVER FUNCTION; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; NEEDLE BIOPSY; POSTMENOPAUSE; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SWEATING; THYROID FUNCTION;

AGED; BREAST; CELL PROLIFERATION; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COLLAGEN; CONTRACEPTIVES, ORAL, SYNTHETIC; DRUG THERAPY, COMBINATION; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGENS; FEMALE; HOT FLASHES; HUMANS; KI-67 ANTIGEN; MAMMOGRAPHY; MIDDLE AGED; NORETHINDRONE; POSTMENOPAUSE; RECEPTORS, ANDROGEN; RECEPTORS, PROGESTERONE; SWEATING;

EID: 84879229426     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/gme.0b013e318276c4ea     Document Type: Article

References (33)

1. The North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 17:242-255.
2. Wren BG. The benefits of oestrogen following menopause: why hormone replacement therapy should be offered to postmenopausal women. Med J Aust 2009; 190:321-325.
3. Hickey M, Davis SR, Sturdee DW Treatment of menopausal symptoms: what shall we do now? Lancet 2005; 366:409-421.
4. Kronenberg F, Fugh-Berman A. Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials. Ann Intern Med 2002; 137:805-813.
5. Nelson HD, Humphrey LL, Nygren P, Teutsch S.M., Allan JD Post-menopausal hormone replacement therapy: scientific review. JAMA 2002; 288:872-881.
6. Smith DC, Prentice R, Thompson D.J., Herrmann WL Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 1975; 293: 1164-1167.
7. Yeh IT. Postmenopausal hormone replacement therapy: endometrial and breast effects. Adv Anat Pathol 2007; 14:17-24.
8. Rossouw JE, Anderson GL, Prentice R.L., et al Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321-333.
9. Chlebowski RT, Hendrix SL, Langer R.D., et al Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA 2003; 289: 3243-3253.
10. McTiernan A, Martin CF, Peck J.D., et al Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial. J Natl Cancer Inst 2005; 97:1366-1376.
11. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362:419-427.
12. Verkooijen HM, Bouchardy C, Vinh-Hung V, Rapiti E., Hartman M. The incidence of breast cancer and changes in the use of hormone replacement therapy: a review of the evidence. Maturitas 2009; 64:80-85.
13. Pines A. Re-think HRT: behind the scene of perceptions. Climacteric 2008; 11:443-446.
14. Gompel A, Rozenberg S, Barlow DH The EMAS 2008 update on clinical recommendations on postmenopausal hormone replacement therapy. Maturitas 2008; 61:227-232.
15. Bluming AZ, Tavris C. Hormone replacement therapy: real concerns and false alarms. Cancer J (Sudbury, Mass) 2009; 15:93-104.
16. Campagnoli C, Clavel-Chapelon F, Kaaks R., Peris C, Berrino F. Pro-gestins and progesterone in hormone replacement therapy and the risk of breast cancer. J Steroid Biochem Mol Biol 2005; 96:95-108.
17. Biglia N, Mariani L, Sgro L., Mininanni P, Moggio G, Sismondi P. Increased incidence of lobular breast cancer in women treated with hormone replacement therapy: implications for diagnosis, surgical and medical treatment. Endocr Relat Cancer 2007; 14:549-567.
18. Stahlberg C, Pedersen AT, Lynge E, Ottesen B. Hormone replacement therapy and risk of breast cancer: the role of progestins. Acta Obstet Gynecol Scand 2003; 82:335-344.
19. Sitruk-Ware R., Plu-Bureau G. Exogenous progestagens and the human breast. Maturitas 2004; 49:58-66.
20. Skouby SO, Jespersen J. Progestins in HRT: sufferance or desire? Maturitas 2009; 62:371-375.
21. Gadducci A, Biglia N, Cosio S., Sismondi P, Genazzani AR Progesta-gen component in combined hormone replacement therapy in postmeno-pausal women and breast cancer risk: a debated clinical issue. Gynecol Endocrinol 2009; 25:807-815.
22. Conner P, Christow A, Kersemaekers W., et al A comparative study of breast cell proliferation during hormone replacement therapy: effects of tibolone and continuous combined estrogen-progestogen treatment. Climacteric 2004; 7:50-58.
23. Conner P, Soderqvist G, Skoog L., et al Breast cell proliferation in post-menopausal women during HRT evaluated through fine needle aspiration cytology. Breast Cancer Res Treat 2003; 78:159-165.
24. Cheng G, Wilczek B, Warner M., Gustafsson JA, Landgren BM Iso-flavone treatment for acute menopausal symptoms. Menopause 2007; 14: 468-473.
25. Collins A, Landgren BM Psychosocial factors associated with the use of hormonal replacement therapy in a longitudinal follow-up of Swedish women. Maturitas 1997; 28:1-9.
26. Wolfe JN. Breast patterns as an index of risk for developing breast cancer. AJR Am J Roentgenol 1976; 126:1130-1139.
27. Yerushalmi R, Woods R, Ravdin P.M., Hayes MM, Gelmon KA Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 2010; 11:174-183.
28. L'Hermite M., Simoncini T, Fuller S., Genazzani AR Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review. Maturitas 2008; 60:185-201.
29. Ross JS, Slodkowska EA, Symmans W.F., Pusztai L., Ravdin PM, Hortobagyi GN The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009; 14:320-368.
30. Slamon DJ, Clark GM, Wong S.G., Levin WJ, Ullrich A, McGuire WL Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235:177-182.
31. Omoto Y, Kobayashi S, Inoue S., et al Evaluation of oestrogen receptor A wild-type and variant protein expression, and relationship with clin-icopathological factors in breast cancers. Eur J Cancer 2002; 38:380-386.
32. Hofling M, Ma L, Sahlin L., et al Expression of the androgen receptor and syndecan-1 in breast tissue during different hormonal treatments in cynomolgus monkeys. Climacteric 2009; 12:72-79.
33. Attardi BJ, Koduri K, Hild SA Relative progestational and androgenic activity of four progestins used for male hormonal contraception assessed in vitro in relation to their ability to suppress LH secretion in the castrate male rat. Mol Cell Endocrinol 2010; 328:16-21.